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ative failure, complications and patient non-compliance.
A population model was applied to follow to the life-long
impact of individuals receiving cataract surgery. Costing
estimates are based on primary data collection in 14 epi-
demiological sub-regions by regional costing teams and
literature review, and were estimated for different cover-
age levels using non-linear cost functions. RESULTS:
Intra- and extra-capsular cataract surgery are cost-
effective ways to reduce the impact of cataract-blindness.
Extra-capsular cataract surgery is more cost-effective
than intra-capsular surgery in all regions considered, and
higher coverage levels are always more cost-effective than
lower coverage levels. Extra-capsular cataract surgery at
a 95% coverage level would avert over 3.8 million dis-
ability adjusted life years per year globally. The cost-
effectiveness ranges from I$69 per DALY in SearD (South
East Asian Region with high child and adult mortality)
to I$2341 per DALY in WprA (Western Paciﬁc Region
with low child and adult mortality). CONCLUSIONS: In
cataract surgery, extra-capsular surgery at high coverage
level is the most cost-effective way for restoring eyesight.
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BURDEN OF ILLNESS OF ECZEMA IN CANADA
Barbeau M, Lalonde H
Novartis Pharma Canada Inc, Dorval, QC, Canada
OBJECTIVES: As no Canadian data exist yet, the objec-
tive of the study is to determine the burden of illness of
patients suffering from eczema in Canada. The resource
use, direct costs, indirect costs, demographics and other
factors affected by eczema were measured over a 1-year
period. METHODS: Patients were recruited through
Community Pharmacists in Canada and were asked to ﬁll
out a four-page survey. Information about gender, age,
marital status, employment status, income, healthcare
practitioner visits, other medical services visits, hospital-
ization, absenteeism at work/school, over-the-counter
(OTC) treatment, household expenses, sleep distur-
bances, severity and duration of the disease, number of
ﬂares and length of each ﬂare and type of insurance cov-
erage were collected. Costs were attached to the different
variables to calculate the burden of illness of eczema for
the whole cohort but the group was also divided by
disease severity. RESULTS: Over 100 patients were
recruited and more than 70 patients have returned the
survey to this point. Each patient has visited a physician
due to his/her eczema at least once in the last 12 months.
The two variables that have had the most impact on the
cost of the disease are the consumption of OTC medica-
tions and the extra household expenses incurred by the
patient. As expected, the burden increases with the sever-
ity of the disease. Nobody was hospitalised due to their
eczema. CONCLUSIONS: Taken individually, the eco-
nomic burden of eczema is not exceptionally high but
given the prevalence of the disease it represents a high
burden for the society. The results are within the range of
what has been published until now. Prescription costs
were not measured directly in this survey and thus the
results are most likely underestimated.
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OBJECTIVES: To investigate the validity of the 39-item
National Eye Institute Visual Function Questionnaire
(NEI-VFQ-39) at baseline in German patients with 
age-related macular generation (AMD). METHODS:
Ongoing prospective observational study in which 137
patients attended a clinic in Germany. Patients belonged
to one of 3 severity classes: 1) early AMD in both eyes (n
= 25); 2) late-stage AMD in one eye and early-stage AMD
in the other eye (n = 71); and 3) late-stage AMD in both
eyes (n = 41). Correlations of baseline scores were calcu-
lated between NEI-VFQ-39 and visual acuity. Baseline
mean scores on the NEI-VFQ-39 were compared for dif-
ferent AMD severity using linear regression adjusting for
gender, age, education, and smoking. RESULTS: Scores
on visual acuity correlated moderately, as expected, with
NEI-VFQ-39 domain scores on General Vision (r = 0.48),
Near Activities (r = 0.52), Distant Activities (r = 0.46),
and Peripheral Vision (r = 0.44). As expected, visual
acuity correlated modestly though meaningfully with
Social Functioning (r = 0.31), Mental Health (r = 0.31),
Role Difﬁculties (r = 0.36), Dependency (r = 0.38),
Driving (r = 0.34), and Color Vision (r = 0.30); visual
acuity showed little or no correlation with General Health
(r = 0.13) and Ocular Pain (r = -0.09). Signiﬁcant differ-
ences (p < 0.01) in mean scores among severity levels of
AMD were observed for all NEI-VFQ-39 domains except
for domains on Driving, General Health, and Ocular
Pain. CONCLUSIONS: The German version of the NEI-
VFQ-39 exhibits baseline validity as a measure of func-
tional impairment in patients with AMD.
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PATIENT REPORTED OUTCOMES AND
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OBJECTIVES: To assess patient satisfaction and eco-
nomic implications associated with a new formulation of
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brimonidine 0.2% ophthalmic solution. METHODS:
Randomized, controlled trials were conducted in 743
patients to evaluate the original formulation vs. the new
formulation. The new formulation reduced the concen-
tration of the active ingredient from 0.2% to 0.15% and
replaced the preservative, benzalkonium chloride (BAK),
with Purite. Patient outcomes assessed were satisfaction
and comfort level with the product. The economic 
evaluation model estimated the annual cost per patient
including pharmacy and medical ofﬁce visits (including
those that may occur due to adverse events.) RESULTS:
More patients were satisﬁed with the new formulation
(83%) than the original (75%) (p < 0.05). Eighty-ﬁve
percent of patients reported the new formulation was
comfortable vs. 79% for the original. Clinical efﬁcacy (as
measured by IOP reduction) was not different between
the groups. Approximately 90% of the new formulation
patients had no reported ocular allergy (OA) vs. 84% of
the patients using the original formulation (p < 0.05).
Incidence of OA was the primary cost driver in compar-
ing the two formulations, as patients who develop an
ocular allergy require additional resources associated
with OA. The economic model estimated the cost of an
OA patient was $200 more or 36% higher per year than
for an OA free patient, which results in higher overall
treatment costs associated with the original formulation.
CONCLUSIONS: Patients receiving the new reformu-
lated 0.15% brimonidine, rated their treatment satisfac-
tion and comfort level higher than patients on the original
formulation while experiencing the same level of efﬁcacy.
The estimated cost savings for ocular allergy-free patients
would have a positive impact on overall treatment costs.
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OBJECTIVES: To study the quality of life (QOL) of
patients with age related macular degeneration (AMD).
METHODS: A group of 81 subjects attending the low
vision and AMD clinic at the Princess Alexandra Eye
Pavilion in Edinburgh were given a battery of tests which
included the VFQ-25. We deﬁned AMD in the following
severity categories: mild, moderate and severe (dry or wet
AMD). In addition to the Quality of Life questionnaires,
patients were given a conjoint analysis task to complete.
The conjoint was to assess aspects of quality of life which
are rarely addressed in conventional questionnaires (i.e.,
patient values and relative importance of different daily
tasks). RESULTS: Background data on the patients
showed a mean age of 77yrs (SD = 6.8); mean binocular
distance logmar of 0.53 (SD = .43); mean binocular near
acuity of 0.7 (SD = 0.44); mean binocular contrast sensi-
tivity (Pelli Robson) of 1.17 (SD = 0.4). Sixty percent of
patients were classed as “severe” AMD, 28% of patients
as “moderate” AMD, and 12% of patients as “mild”
AMD. Results showed that the most signiﬁcant changes
in quality of life as reported through the questionnaires
occurred at the transition between moderate and severe
forms of the disease. The exception was emotionally rel-
evant questions and patient conﬁdence, which showed a
decline between all three AMD states. In addition con-
joint analysis showed that practical tasks associated with
independence had highest priority—that is the order 
of perceived importance from a 5-attribute conjoint task
was outdoor mobility, household chores, reading, recog-
nising faces, and glare. This rank order was preserved in
a shorter 3 attribute conjoint task given to patients with
extremely poor vision. CONCLUSIONS: The most sig-
niﬁcant change in QOL occurred between moderate and
severe forms of the disease. Patient concerns were mainly
over mobility and household tasks, suggesting a priority
for preserving an independent lifestyle.
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AN APPRAISAL OF VISION-RELATED QUALITY
OF LIFE INSTRUMENTS
Mallya U, Nau DP
University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: Visual impairment has been identiﬁed as
one of the most signiﬁcant contributors to lost indepen-
dence, affecting 1.3 million people in the USA. An empha-
sis on improvement of functional limitations among
patients with visual impairment has led to the develop-
ment of vision-related quality of life (QOL) question-
naires in the recent past. The objective of this paper is 
to provide an updated review of published literature on
vision-related QOL instruments and an assessment of
their psychometric properties. METHODS: A review 
of published literature was carried out through the use 
of MEDLINE and QOLID in order to identify vision
related QOL instruments. The instruments were reviewed
in terms of reliability, validity and sensitivity/responsive-
ness, as well as their length and applicability to various
eye disorders. RESULTS: Twenty-four vision-related
QOL instruments were identiﬁed, of which thirteen were
designed for self-administration. Length of the question-
naires varied from 10 to 136 items, and the structure of
scales also varied greatly. Most of the instruments showed
high internal consistency of scales but only few demon-
strated test-retest reliability. Ten of the instruments
focused primarily on visual function, while fourteen also
measured the impact of vision problems on functional
ability. The NEI-VFQ (51 items) and NEI-VFQ-25 are the
only self-administered questionnaires that evaluate eye-
related functional ability and that have shown evidence
of validity, internal consistency and responsiveness across
a broad range of eye disorders including glaucoma,
